Targeting eosinophils in allergy, inflammation and beyond

Nature Reviews Drug Discovery

Volumn 12, Issue 2, 2013, Pages 117-129

  Fulkerson, Patricia C ^a   Rothenberg, Marc E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; BERTILIMUMAB; CELL ADHESION MOLECULE; CHEMOATTRACTANT RECEPTOR OF TH2 CELL; CHEMOKINE RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR CCR3; EOTAXIN; HISTAMINE H2 RECEPTOR; IMATINIB; IMMUNOGLOBULIN E; IMMUNOLOGIC AGENT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; MONOCLONAL ANTIBODY AMG 157; OMALIZUMAB; PLACEBO; PROSTAGLANDIN D2; RECEPTOR PROTEIN; RESLIZUMAB; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 8; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGY; ASTHMA; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CELL SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; NONHUMAN; NOSE OBSTRUCTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME;

ANIMALS; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; INFLAMMATION; MOLECULAR TARGETED THERAPY;

EID: 84873408369     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3838     Document Type: Review

References (170)

1. Lee, J. J. et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305, 1773-1776 (2004).
2. Humbles, A. A. et al. A critical role for eosinophils in allergic airways remodeling. Science 305, 1776-1779 (2004).
3. Castro, M. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184, 1125-1132 (2011).
4. Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984 (2009).
5. Jacobsen, E. A., Helmers, R. A., Lee, J. J. & Lee, N. A. The expanding role(s) of eosinophils in health and disease. Blood 120, 3882-3890 (2012).
6. Lee, J. J., Jacobsen, E. A., McGarry, M. P., Schleimer, R. P. & Lee, N. A. Eosinophils in health and disease: the LIAR hypothesis. Clin. Exp. Allergy 40, 563-575 (2010).
7. Lowe, D., Jorizzo, J. & Hutt, M. S. Tumour-associated eosinophilia: a review. J. Clin. Pathol. 34, 1343-1348 (1981).
8. Cormier, S. A. et al. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 79, 1131-1139 (2006).
9. Simson, L. et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol. 178, 4222-4229 (2007).
10. Chu, V. T. et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nature Immunol. 12, 151-159 (2011).
11. Chu, V. T. & Berek, C. Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur. J. Immunol. 42, 130-137 (2012).
12. Hruz, P. et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J. Allergy Clin. Immunol. 128, 1349-1350 (2011).
13. Bohm, M. et al. Mucosal eosinophilia: prevalence and racial/ethnic differences in symptoms and endoscopic findings in adults over 10 years in an urban hospital. J. Clin. Gastroenterol. 46, 567-574 (2011).
14. Mori, Y. et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J. Exp. Med. 206, 183-193 (2009).
15. Iwasaki, H. et al. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J. Exp. Med. 201, 1891-1897 (2005).
16. + cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. J. Clin. Invest. 100, 2466-2475 (1997).
17. Hogan, S. P. et al. Eosinophils: biological properties and role in health and disease. Clin. Exp. Allergy 38, 709-750 (2008).
18. Ahlstrom-Emanuelsson, C. A., Greiff, L., Andersson, M., Persson, C. G. & Erjefalt, J. S. Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure. Eur. Respir. J. 24, 750-757 (2004).
19. Filley, W. V., Holley, K. E., Kephart, G. M. & Gleich, G. J. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 2, 11-16 (1982).
20. Kephart, G. M. et al. Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am. J. Gastroenterol. 105, 298-307 (2010).
21. Noguchi, H., Kephart, G. M., Colby, T. V. & Gleich, G. J. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol. 140, 521-528 (1992).
22. Chung, H. L. et al. Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the mucosa of the small intestine in infants with cow's milk-sensitive enteropathy. J. Allergy Clin. Immunol. 103, 1195-1201 (1999).
23. Brottman, G. M., Regelmann, W. E., Slungaard, A. & Wangensteen, O. D. Effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatr. Pulmonol. 21, 159-166 (1996).
24. Gleich, G. J., Frigas, E., Loegering, D. A., Wassom, D. L. & Steinmuller, D. Cytotoxic properties of the eosinophil major basic protein. J. Immunol. 123, 2925-2927 (1979).
25. Tai, P. C., Hayes, D. J., Clark, J. B. & Spry, C. J. Toxic effects of human eosinophil products on isolated rat heart cells in vitro. Biochem. J. 204, 75-80 (1982).
26. Rosenberg, H. F. Eosinophil-derived neurotoxin/RNase 2: connecting the past, the present and the future. Curr. Pharm. Biotechnol. 9, 135-140 (2008).
27. Domachowske, J. B., Dyer, K. D., Bonville, C. A. & Rosenberg, H. F. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J. Infect. Dis. 177, 1458-1464 (1998).
28. Hernnas, J. et al. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur. J. Cell Biol. 59, 352-363 (1992).
29. Muniz, V. S., Weller, P. F. & Neves, J. S. Eosinophil crystalloid granules: structure, function, and beyond. J. Leukoc. Biol. 92, 281-288 (2012).
30. Meagher, L. C., Cousin, J. M., Seckl, J. R. & Haslett, C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156, 4422-4428 (1996).
31. Druilhe, A., Letuve, S. & Pretolani, M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 8, 481-495 (2003).
32. Her, E., Frazer, J., Austen, K. F. & Owen, W. F. Jr. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J. Clin. Invest. 88, 1982-1987 (1991).
33. Jain, N. et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status. Leuk. Res. 33, 837-839 (2009).
34. Ogbogu, P. U. et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J. Allergy Clin. Immunol. 124, 1319-1325 (2009).
35. Hamelmann, E. et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 160, 934-941 (1999).
36. Rothenberg, M. E. et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 358, 1215-1228 (2008).
37. Stein, M. L. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118, 1312-1319 (2006).
38. Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651-659 (2012).
39. Gong, L. & Wilhelm, R. S. CCR3 antagonists: a survey of the patent literature. Expert Opin. Ther. Pat. 19, 1109-1132 (2009).
40. Pease, J. E. & Williams, T. J. Eotaxin and asthma. Curr. Opin. Pharmacol. 1, 248-253 (2001).
41. 2+-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Blood 88, 3195-3199 (1996).
42. Kampen, G. T. et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95, 1911-1917 (2000).
43. Fulkerson, P. C., Fischetti, C. A. & Rothenberg, M. E. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am. J. Pathol. 169, 2117-2126 (2006).
44. Fulkerson, P. C. et al. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc. Natl Acad. Sci. USA 103, 16418-16423 (2006).
45. Ahrens, R. et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J. Immunol. 181, 7390-7399 (2008).
46. + inflammatory monocyte/macrophage-derived CCL11. J. Immunol. 186, 5993-6003 (2011).
47. Ying, S. et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol. 27, 3507-3516 (1997).
48. Wegmann, M. et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell. Mol. Biol. 36, 61-67 (2007).
49. Komai, M. et al. A novel CC-chemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial/peribronchial fibrosis induced by repeated antigen challenge in mice. J. Pharmacol. Sci. 11 2, 203-213 (2010).
50. Ding, C., Li, J. & Zhang, X. Bertilimumab Cambridge Antibody Technology Group. Curr. Opin. Investig. Drugs 5, 1213-1218 (2004).
51. Blanchard, C. et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest. 116, 536-547 (2006).
52. Zuo, L. et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13Rα2-inhibited pathway. J. Immunol. 185, 660-669 (2010).
53. Mattes, J. et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J. Exp. Med. 195, 1433-1444 (2002).
54. Nakajima, H., Sano, H., Nishimura, T., Yoshida, S. & Iwamoto, I. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J. Exp. Med. 179, 1145-1154 (1994).
55. Henderson, W. R. Jr et al. Blockade of CD49d (α4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. 100, 3083-3092 (1997).
56. Okigami, H. et al. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur. J. Pharmacol. 559, 202-209 (2007).
57. Abbas, M. et al. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. Neurology 77, 1561-1564 (2011).
58. Schleimer, R. P. et al. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J. Allergy Clin. Immunol. 76, 369-374 (1985).
59. Schratl, P. et al. The role of the prostaglandin D2 receptor, D P, in eosinophil trafficking. J. Immunol. 179, 4792-4799 (2007).
60. Royer, J. F. et al. A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst. Allergy 62, 1401-1409 (2007).
61. Hirai, H. et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255-261 (2001).
62. Kagawa, S. et al. Role of prostaglandin D2 receptor CRTH2 in sustained eosinophil accumulation in the airways of mice with chronic asthma. Int. Arch. Allergy Immunol. 155 (Suppl. 1), 6-11 (2011).
63. Heinemann, A., Schuligoi, R., Sabroe, I., Hartnell, A. & Peskar, B. A. δ12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J. Immunol. 170, 4752-4758 (2003).
64. Sugimoto, H. et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J. Pharmacol. Exp. Ther. 305, 347-352 (2003).
65. Schuligoi, R. et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 85, 372-382 (2010).
66. Barnes, N. et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin. Exp. Allergy 42, 38-48 (2012).
67. Green, R. H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715-1721 (2002).
68. Straumann, A. et al. 856 treatment of eosinophilic esophagitis with the CRTH2-antagonist Oc000459: a novel therapeutic principle. Gastroenterology 142 (Suppl. 1), 147 (2012).
69. O'Reilly, M. et al. Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. J. Recept. Signal Transduct. Res. 22, 431-448 (2002).
70. Ling, P. et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. J. Pharmacol. 142, 161-171 (2004).
71. 4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur. J. Pharmacol. 675, 47-56 (2012).
72. Zampeli, E. & Tiligada, E. The role of histamine H4 receptor in immune and inflammatory disorders. Br. J. Pharmacol. 157, 24-33 (2009).
73. Yu, S., Stahl, E., Li, Q. & Ouyang, A. Antigen inhalation induces mast cells and eosinophils infiltration in the guinea pig esophageal epithelium involving histamine-mediated pathway. Life Sci. 82, 324-330 (2008).
74. Thurmond, R. L., Gelfand, E. W. & Dunford, P. J. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nature Rev. Drug Discov. 7, 41-53 (2008).
75. Finkelman, F. D., Hogan, S. P., Hershey, G. K., Rothenberg, M. E. & Wills-Karp, M. Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol. 184, 1663-1674 (2010).
76. Sherrill, J. D. & Rothenberg, M. E. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J. Allergy Clin. Immunol. 128, 23-32 (2011).
77. Pope, S. M. et al. IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism. J. Allergy Clin. Immunol. 108, 594-601 (2001).
78. Pope, S. M. et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. J. Biol. Chem. 280, 13952-13961 (2005).
79. Blanchard, C. et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J. Allergy Clin. Immunol. 120, 1292-1300 (2007).
80. Huang, S. K. et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J. Immunol. 155, 2688-2694 (1995).
81. Prieto, J. et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir. Med. 94, 806-814 (2000).
82. Gauvreau, G. M. et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007-1014 (2011).
83. Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088-1098 (2011).
84. Nicholson, G. C. et al. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J. Allergy Clin. Immunol. 128, 800-807 (2011).
85. Tomkinson, A. et al. A murine IL-4 receptor antagonist that inhibits IL-4-and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 166, 5792-5800 (2001).
86. Munitz, A., Brandt, E. B., Mingler, M., Finkelman, F. D. & Rothenberg, M. E. Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc. Natl Acad. Sci. USA 105, 7240-7245 (2008).
87. Corren, J. et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am. J. Respir. Crit. Care Med. 181, 788-796 (2010).
88. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422-1431 (2007).
89. Nair, P. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360, 985-993 (2009).
90. Catley, M. C., Coote, J., Bari, M. & Tomlinson, K. L. Monoclonal antibodies for the treatment of asthma. Pharmacol. Ther. 132, 333-351 (2011).
91. Rothenberg, M. E. & Hogan, S. P. The eosinophil. Annu. Rev. Immunol. 24, 147-174 (2006).
92. Takatsu, K. Interleukin-5 and IL-5 receptor in health and diseases. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 87, 463-485 (2011).
93. Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. & Geba, G. P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin. Exp. Allergy 42, 712-737 (2012).
94. Neves, J. S. & Weller, P. F. Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. Curr. Opin. Immunol. 21, 694-699 (2009).
95. Stern, M., Meagher, L., Savill, J. & Haslett, C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J. Immunol. 148, 3543-3549 (1992).
96. Tai, P. C., Sun, L. & Spry, C. J. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin. Exp. Immunol. 85, 312-316 (1991).
97. Yamaguchi, Y. et al. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78, 2542-2547 (1991).
98. Assa'ad, A. H. et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141, 1593-1604 (2011).
99. Straumann, A. et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59, 21-30 (2010).
100. Gevaert, P. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 128, 989-995 (2011).
101. Spergel, J. M. et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 129, 456-463.e3 (2012).
102. Kips, J. C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003).
103. Kolbeck, R. et al. MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 125, 1344-1353 (2010).
104. Busse, W. W. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 125, 1237-1244 (2010).
105. Imaoka, H. et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin. Exp. Allergy 41, 1740-1746 (2011).
106. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleo-tides. Nature Rev. Drug Discov. 11, 125-140 (2012).
107. Burnett, J. C. & Rossi, J. J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-71 (2012).
108. Graziewicz, M. A. et al. An endogenous TNF-α antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol. Ther. 16, 1316-1322 (2008).
109. Bochner, B. S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy 39, 317-324 (2009).
110. Nutku, E., Aizawa, H., Hudson, S. A. & Bochner, B. S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101, 5014-5020 (2003).
111. Zhang, M. et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109, 4280-4287 (2007).
112. Zimmermann, N. et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63, 1156-1163 (2008).
113. Song, D. J. et al. Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin. Immunol. 131, 157-169 (2009).
114. Kiwamoto, T., Kawasaki, N., Paulson, J. C. & Bochner, B. S. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol. Ther. 135, 327-336 (2012).
115. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
116. Soler, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254-261 (2001).
117. Holgate, S. T. et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 34, 632-638 (2004).
118. Holgate, S. T., Djukanovic, R., Casale, T. & Bousquet, J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35, 408-416 (2005).
119. Djukanovic, R. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170, 583-593 (2004).
120. Massanari, M. et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir. Med. 104, 188-196 (2010).
121. Noga, O. et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J. Allergy Clin. Immunol. 117, 1493-1499 (2006).
122. Foroughi, S. et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J. Allergy Clin. Immunol. 120, 594-601 (2007).
123. Ravetch, J. V. & Lanier, L. L. Immune inhibitory receptors. Science 290, 84-89 (2000).
124. Cooper, M. D. Inhibition of immune cell function. Immunol. Rev. 224, 7-10 (2008).
125. Munitz, A. & Levi-Schaffer, F. Inhibitory receptors on eosinophils: a direct hit to a possible Achilles heel? J. Allergy Clin. Immunol. 119, 1382-1387 (2007).
126. Munitz, A. Inhibitory receptors on myeloid cells: new targets for therapy? Pharmacol. Ther. 125, 128-137 (2010).
127. Munitz, A. et al. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 107, 1996-2003 (2006).
128. Verjan, G. N. et al. SIRPα/CD172a regulates eosinophil homeostasis. J. Immunol. 187, 2268-2277 (2011).
129. Munitz, A., McBride, M. L., Bernstein, J. S. & Rothenberg, M. E. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood 111, 5694-5703 (2008).
130. Bachelet, I., Munitz, A. & Levi-Schaffer, F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J. Allergy Clin. Immunol. 117, 1314-1320 (2006).
131. Park, L. S. et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 192, 659-670 (2000).
132. Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature Immunol. 3, 673-680 (2002).
133. Rimoldi, M. et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nature Immunol. 6, 507-514 (2005).
134. Zhang, Y. & Zhou, B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol. Res. 52, 211-223 (2012).
135. Osborn, M. J. et al. Overexpression of murine TSLP impairs lymphopoiesis and myelopoiesis. Blood 103, 843-851 (2004).
136. Wong, C. K., Hu, S., Cheung, P. F. & Lam, C. W. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am. J. Respir. Cell Mol. Biol. 43, 305-315 (2010).
137. Morshed, M., Yousefi, S., Stockle, C., Simon, H. U. & Simon, D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 67, 1127-1137 (2012).
138. Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nature Genet. 41, 342-347 (2009).
139. Rothenberg, M. E. et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nature Genet. 42, 289-291 (2010).
140. Klion, A. D. et al. Familial eosinophilia: a benign disorder? Blood 103, 4050-4055 (2004).
141. Bates, M. E. et al. Human airway eosinophils respond to chemoattractants with greater eosinophil-derived neurotoxin release, adherence to fibronectin, and activation of the Ras-ERK pathway when compared with blood eosinophils. J. Immunol. 184, 7125-7133 (2010).
142. Sedgwick, J. B. et al. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J. Immunol. 149, 3710-3718 (1992).
143. Coffer, P. J. & Koenderman, L. Granulocyte signal transduction and priming: cause without effect? Immunol. Lett. 57, 27-31 (1997).
144. Kariyawasam, H. H. & Robinson, D. S. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin. Respir. Crit. Care Med. 27, 117-127 (2006).
145. Stein, M. L. et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol. 121, 1473-1483.e4 (2008).
146. Pecaric-Petkovic, T., Didichenko, S. A., Kaempfer, S., Spiegl, N. & Dahinden, C. A. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526-1534 (2009).
147. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. & Kita, H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490 (2008).
148. Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D. & Liew, F. Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 185, 3472-3480 (2010).
149. Kim, Y. H. et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 67, 183-190 (2012).
150. Liu, X. et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386, 181-185 (2009).
151. Yin, H. et al. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice. Clin. Exp. Immunol. 170, 1-9 (2012).
152. Kang, J. H. et al. Regulation of functional phenotypes of cord blood derived eosinophils by γ-secretase inhibitor. Am. J. Respir. Cell Mol. Biol. 37, 571-577 (2007).
153. Radke, A. L. et al. Mature human eosinophils express functional Notch ligands mediating eosinophil autocrine regulation. Blood 113, 3092-3101 (2009).
154. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
155. Eagar, T. N. et al. Notch 1 signaling regulates peripheral T cell activation. Immunity 20, 407-415 (2004).
156. Kang, J. H. et al. Eosinophilic differentiation is promoted by blockage of Notch signaling with a γ-secretase inhibitor. Eur. J. Immunol. 35, 2982-2990 (2005).
157. Siemers, E. R. et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604 (2006).
158. Cameron, L. et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J. Immunol. 164, 1538-1545 (2000).
159. + cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am. J. Respir. Cell Mol. Biol. 20, 9-13 (1999).
160. + hemopoietic progenitor cells are potent effectors of allergic inflammation. J. Allergy Clin. Immunol. 123, 472-478 (2009).
161. Menzies-Gow, A. et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 111, 714-719 (2003).
162. Mejia, R. & Nutman, T. B. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin. Hematol. 49, 149-159 (2012).
163. Simon, H. U. et al. Refining the definition of hypereosinophilic syndrome. J. Allergy Clin. Immunol. 126, 45-49 (2010).
164. Caldwell, J. M. et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J. Allergy Clin. Immunol. 125, 879-888 (2010).
165. Blanchard, C. et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J. Allergy Clin. Immunol. 127, 208-217 (2011).
166. Rothenberg, M. E. Biology and treatment of eosinophilic esophagitis. Gastroenterology 137, 1238-1249 (2009).
167. Dellon, E. S., Chen, X., Miller, C. R., Woosley, J. T. & Shaheen, N. J. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am. J. Gastroenterol. 107, 1503-1511 (2012).
168. Valent, P. et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J. Allergy Clin. Immunol. 130, 607-612 (2012).
169. Roufosse, F. & Weller, P. F. Practical approach to the patient with hypereosinophilia. J. Allergy Clin. Immunol. 126, 39-44 (2010).
170. Klion, A. D. How I treat hypereosinophilic syndromes. Blood 114, 3736-3741 (2009).